Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Follow-Up Questions
IFTBF 股票的價格表現如何？
IFTBF 的當前價格為 $0，在上個交易日 decreased 了 0%。
Infant Bacterial Therapeutics AB 的主要業務主題或行業是什麼？
Infant Bacterial Therapeutics AB 屬於 Pharmaceuticals 行業，該板塊是 Health Care
